Fb. Gabbai et al., INHIBITION OF INDUCIBLE NITRIC-OXIDE SYNTHASE INTENSIFIES INJURY AND FUNCTIONAL DETERIORATION IN AUTOIMMUNE INTERSTITIAL NEPHRITIS, The Journal of immunology, 159(12), 1997, pp. 6266-6275
T lymphocytes are exquisitely sensitive to the antiproliferative effec
ts of nitric oxide. We examined the effects of oral administration of
two nitric oxide synthase inhibitors, N-w-nitro-L-arginine methyl este
r (L-NAME) and L-N-6-(1-iminoethyl)lysine (L-NIL), on the course of T
cell-dependent autoimmune interstitial nephritis in Brown Norway rats.
Kidneys from rats immunized to produce interstitial nephritis display
a net generation of nitric oxide end products. By immunohistochemical
staining, the cytokine-inducible nitric oxide synthase (iNOS) is expr
essed in cortical tubular epithelial cells. Treatment with either inhi
bitor results in markedly more severe disease following immunization.
Animals receiving L-NAME were hypertensive, while those treated with L
-NlL, a highly selective inhibitor of iNOS, were not. Evaluation of th
e expression of IFN-gamma, IL-2, and IL-4 in diseased kidneys by quant
itative reverse transcriptase-PCR demonstrated that L-NAME-treated ani
mals displayed significantly augmented levels of lFN-gamma and IL-2 wi
th preserved ratios of IFN-gamma/IL-4 and IL-2/IL-4, while L-NIL-treat
ed animals had augmented levels of IL-2 and IFN-gamma with augmented I
FN-gamma/IL-4 and IL-2/IL-4 ratios. Animals treated with L-NAME or L-N
IL both had augmented Ag-specific Ige responses. The L-NAME group demo
nstrated increases in both the IgG2a and IgG1 subtypes, with a constan
t IgG2a/IgG1 ratio, while the L-NIL group demonstrated an increase in
the ratio of the IgG2a/IgG1 response. These Ab and cytokine data sugge
st that the L-NIL-treated animals had a skewing of their immune respon
se toward a Th1-like response. We conclude that in autoimmune intersti
tial nephritis, generation of nitric oxide through the iNOS pathway ha
s host-protective effects, and suggest that this may be broadly applic
able to T cell-mediated pathologies.